# Sodium Valproate ```text DRUG INFORMATION ADULT - Epilepsy Complex Partial Seizures in Adults and Children 10 years of age or older: Initial dose is 10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day to achieve optimal clinical response. Source: US FDA label for valproate sodium (Valproate Sodium), section 'dosage and administration', retrieved 2026-08-29 - Maximum recommended dose is 60 mg/kg/day ( 2.1 ). Source: US FDA label for valproate sodium (Valproate Sodium), section 'dosage and administration', retrieved 2026-08-29 - Simple and Complex Absence Seizures: Initial dose is 10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day to achieve optimal clinical response. Source: US FDA label for valproate sodium (Valproate Sodium), section 'dosage and administration', retrieved 2026-08-29 CHILD - Experience with oral valproate has indicated that pediatric patients under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those with the aforementioned conditions [see BOXED WARNING ]. The safety of Valproate Sodium Injection has not been studied in individuals below the age of 2 years. Source: US FDA label for valproate sodium (Valproate Sodium), section 'pediatric use', retrieved 2026-08-29 - Valproate Sodium Injection is intended for intravenous use only. Epilepsy Complex Partial Seizures in Adults and Children 10 years of age or older: Initial dose is 10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day to achieve optimal clinical response. Maximum recommended dose is 60 mg/kg/day ( 2.1 ). Source: US FDA label for valproate sodium (Valproate Sodium), section 'dosage and administration', retrieved 2026-08-29 - Epilepsy Complex Partial Seizures in Adults and Children 10 years of age or older: Initial dose is 10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day to achieve optimal clinical response. Source: US FDA label for valproate sodium (Valproate Sodium), section 'dosage and administration', retrieved 2026-08-29 RENAL IMPAIRMENT - No kidney-impairment dose in this label. Not a statement that none is needed. Source: Read and found silent: the US FDA label for valproate sodium (Valproate Sodium), retrieved 2026-08-29 HEPATIC IMPAIRMENT - Valproate-induced acute liver failure and liver-related deaths have been reported in patients with hereditary neurometabolic syndromes caused by mutations in the gene for mitochondrial DNA polymerase γ (POLG) (e.g., Alpers- Huttenlocher Syndrome) at a higher rate than those without these syndromes. Source: US FDA label for valproate sodium (Valproate Sodium), section 'warnings and cautions', retrieved 2026-08-29 - Most of the reported cases of liver failure in patients with these syndromes have been identified in children and adolescents. Source: US FDA label for valproate sodium (Valproate Sodium), section 'warnings and cautions', retrieved 2026-08-29 PREGNANCY - Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), including Valproate Sodium Injection, during pregnancy. Source: US FDA label for valproate sodium (Valproate Sodium), section 'pregnancy', retrieved 2026-08-29 - Encourage women who are taking Valproate Sodium Injection during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling toll free 1-888-233-2334 or visiting the website, http://www.aedpregnancyregistry.org/. Source: US FDA label for valproate sodium (Valproate Sodium), section 'pregnancy', retrieved 2026-08-29 - This must be done by the patient herself. Source: US FDA label for valproate sodium (Valproate Sodium), section 'pregnancy', retrieved 2026-08-29 BREASTFEEDING - Risk Summary Valproate is excreted in human milk. Source: US FDA label for valproate sodium (Valproate Sodium), section 'nursing mothers', retrieved 2026-08-29 - Data in the published literature describe the presence of valproate in human milk (range: 0.4 mcg/mL to 3.9 mcg/mL), corresponding to 1% to 10% of maternal serum levels. Source: US FDA label for valproate sodium (Valproate Sodium), section 'nursing mothers', retrieved 2026-08-29 - Valproate serum concentrations collected from breastfed infants aged 3 days postnatal to 12 weeks following delivery ranged from 0.7 mcg/mL to 4 mcg/mL, which were 1% to 6% of maternal serum valproate levels. Source: US FDA label for valproate sodium (Valproate Sodium), section 'nursing mothers', retrieved 2026-08-29 ``` --- Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement. [Privacy policy](/privacy)